TGFB1 and pancreatic neoplasm: For instance, Porcelli et al. demonstrated that mast cells induce the release of TGF-β1 and chemotherapy resistance in pancreatic cancer cells in vitro, through a mechanism dependent on ERK1/2 and Akt signaling activation, which are common in pancreatic cancer because of KRAS mutations [35].